Pain management最新文献_第5页

Patient and staff perspectives on pain treatment experiences in a community clinic serving under-resourced older adults. 在一家为资源匮乏的老年人服务的社区诊所中，病人和员工对疼痛治疗经验的看法。

IF 1.4

Pain management Pub Date : 2024-10-01 Epub Date: 2024-11-27 DOI: 10.1080/17581869.2024.2432852

Julie R Brewer, Katherine A McDermott, Jonathan Greenberg, Alexander M Presciutti, Danielle E LaCamera, Christine S Ritchie, Ana-Maria Vranceanu

{"title":"Patient and staff perspectives on pain treatment experiences in a community clinic serving under-resourced older adults.","authors":"Julie R Brewer, Katherine A McDermott, Jonathan Greenberg, Alexander M Presciutti, Danielle E LaCamera, Christine S Ritchie, Ana-Maria Vranceanu","doi":"10.1080/17581869.2024.2432852","DOIUrl":"10.1080/17581869.2024.2432852","url":null,"abstract":"Aims: Chronic pain affects up to 37.8% of older adults with higher prevalence among those in under-resourced communities. While there are many treatments for chronic pain, there are complexities to treating under-resourced older adults in community clinics, including multimorbidity, barriers to treatment access, and varying degrees of openness to different treatment approaches. Understanding patient and clinic staff perceptions of treatment options for chronic pain is critical for implementing treatment approaches that will work sustainably in the community. This study aimed to understand clinic staff and patients' perspectives on chronic pain treatment experiences.Methods: Focus groups and individual interviews were analyzed using a hybrid inductive-deductive approach.Results: Themes are: (1) Limited patient and clinic resources and availability affecting pain treatment experiences (e.g., copays, transportation challenges, and conflicting responsibilities), (2) Discrepancies in patient and staff approaches to treatment and the importance of trialing different pain management techniques to alleviate pain (e.g., trialing multiple treatments with varied success), and (3) Conflict between patients' desire for pain elimination vs. staffs' focus on symptom reduction and function (e.g., patient-staff disconnect).Conclusions: These findings are important for determining how treatments can best fit the needs of under-resourced older adults with chronic pain.","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"549-556"},"PeriodicalIF":1.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11633828/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142731825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Spinal cord stimulation in a patient with an implantable cardioverter defibrillator for managing chronic chest pain: a case report and literature review. 植入式心脏除颤器患者脊髓刺激治疗慢性胸痛：病例报告和文献综述。

IF 1.4

Pain management Pub Date : 2024-10-01 Epub Date: 2024-11-14 DOI: 10.1080/17581869.2024.2426971

Porras Bueno Cristian Orlando, Rangel Jaimes German William, Camargo Cárdenas Anamaria, Cediel Carrillo Ximena, Berdugo Pereira Eliana Milena

引用次数: 0

Antidepressants for pain in adults. 治疗成人疼痛的抗抑郁药。

IF 1.4

Pain management Pub Date : 2024-10-01 Epub Date: 2024-11-24 DOI: 10.1080/17581869.2024.2432281

Giovanni E Ferreira, Hanan McLachlan, Andrew J McLachlan

引用次数: 0

The efficacy of topical 8% capsaicin patches for the treatment of postsurgical neuropathic pain: a systematic review. 8%辣椒素外用贴片治疗手术后神经病理性疼痛的疗效：系统性综述。

IF 1.4

Pain management Pub Date : 2024-10-01 Epub Date: 2024-11-26 DOI: 10.1080/17581869.2024.2433931

Brandon Goodwin, Jessica Mitchell, Erin Major, Alicia Podwojniak, Hanna Brancaccio, Katarina Rusinak, Matthew King, Hassan Tahir

{"title":"The efficacy of topical 8% capsaicin patches for the treatment of postsurgical neuropathic pain: a systematic review.","authors":"Brandon Goodwin, Jessica Mitchell, Erin Major, Alicia Podwojniak, Hanna Brancaccio, Katarina Rusinak, Matthew King, Hassan Tahir","doi":"10.1080/17581869.2024.2433931","DOIUrl":"10.1080/17581869.2024.2433931","url":null,"abstract":"Objective: To investigate the benefits of topical 8% capsaicin patches for the decrease of postsurgical neuropathic pain level and area.Methods: A systematic review with pooled analysis was conducted utilizing the PRISMA 2020 guidelines. Five commonly used databases were employed utilizing a search string made from MeSH terms and boolean operators. Retrieved articles were then subjected to title and abstract appraisal, followed by full-text appraisal by two independent reviewers and an adjudicator to break ties.Results: A total of 127 articles were retrieved from five commonly used databases. Of the 127 articles, 20 were subjected to full-text appraisal, with 12 remaining for inclusion. Due to a heterogeneity greater than the 50% threshold provided by Cochrane, a random-effects pooled-analysis was conducted in lieu of meta-analysis. The random-effects pooled-analysis denotes an overall Cohen's d of 1.09 (95% CI: 0.58-1.56; p < 0.001). All studies that investigated neuropathic pain area denote a decrease in pain size, with some denoting a continued reduction with subsequent application.Conclusion: Further larger randomized-controlled trials are required to strengthen the position of topical capsaicin patches in the physician's armamentarium.Protocol registration: www.crd.york.ac.uk/prospero identifier is CRD42024542508.","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"591-598"},"PeriodicalIF":1.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11622774/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142716817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A novel approach to refractory coccydynia: ultrasound- fluoroscopy-guided cryoablation of sacrococcygeal nerve. 治疗难治性尾骨痛的新方法：超声-透视引导下的骶尾部神经冷冻消融术。

IF 1.4

Pain management Pub Date : 2024-10-01 Epub Date: 2024-11-17 DOI: 10.1080/17581869.2024.2430162

Inês Mendes-Andrade, Robert Pagan-Rosado, Nuno Ferreira-Silva, Mark Friedrich Hurdle

引用次数: 0

Efficacy of transdermal anti-inflammatory patches for musculoskeletal pain: a systematic review and meta-analysis. 透皮消炎贴对肌肉骨骼疼痛的疗效：系统综述和荟萃分析。

IF 1.4

Pain management Pub Date : 2024-10-01 Epub Date: 2024-11-22 DOI: 10.1080/17581869.2024.2421153

María B Sánchez, Michael J Callaghan, James Selfe, Michael Twigg, Toby Smith

{"title":"Efficacy of transdermal anti-inflammatory patches for musculoskeletal pain: a systematic review and meta-analysis.","authors":"María B Sánchez, Michael J Callaghan, James Selfe, Michael Twigg, Toby Smith","doi":"10.1080/17581869.2024.2421153","DOIUrl":"10.1080/17581869.2024.2421153","url":null,"abstract":"Aim: To determine the efficacy of transdermal anti-inflammatory patches in the treatment of acute and chronic musculoskeletal pain.Methods: A comprehensive search of: Cochrane Central register of controlled trials, EMBASE, MEDLINE, CINAHL and PubMed, for studies using transdermal anti-inflammatory patches vs placebo for management of musculoskeletal pain, e.g. soft tissue injuries or tendonitis (last search January 2024). Cochrane Risk of Bias Tools v1 was used for quality assessment and GRADE determined certainty of evidence. Meta-analysis was performed.Results: Twenty-three randomized placebo-controlled trials (n = 4729) were included. There was low-certainty evidence that transdermal patches provided statistically and clinically significant pain relief on movement at long-term follow-up for chronic musculoskeletal pain (effect size -2-69 (95% CI: -4.14, -1.24) and at short-term follow-up which was non-clinically significant, (-1.24: 95% CI: -1.78, -0.69).Conclusion: Several types of transdermal anti-inflammatory patches may offer short-term and long-term pain relief for acute and chronic musculoskeletal conditions. However, the clinical significance of this effect for the long-term pain relief was based on low-certainty evidence of transdermal anti-inflammatory patches versus placebo; for short-term pain there was an overall non-clinically significant improvement. Performing a meta-analysis for all outcomes was not possible due to insufficiency in the evidence-base.Protocol registration: www.crd.york.ac.uk/prospero identifier is CRD42020185944.","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"557-569"},"PeriodicalIF":1.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730417/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142688410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Galcanezumab add-on in refractory cluster headache. A case series. 加群单抗用于难治性丛集性头痛。病例系列。

IF 1.4

Pain management Pub Date : 2024-09-01 Epub Date: 2024-11-18 DOI: 10.1080/17581869.2024.2427564

Georgios Karagiorgis, Savvas Christofilos, Christina Deligianni, Ioanna Spanou, Sofia Vassilopoulou, Dimos-Dimitrios D Mitsikostas

{"title":"Galcanezumab add-on in refractory cluster headache. A case series.","authors":"Georgios Karagiorgis, Savvas Christofilos, Christina Deligianni, Ioanna Spanou, Sofia Vassilopoulou, Dimos-Dimitrios D Mitsikostas","doi":"10.1080/17581869.2024.2427564","DOIUrl":"10.1080/17581869.2024.2427564","url":null,"abstract":"Cluster headache (CH), a highly disabling condition, lacks disease-specific, mechanism-based prophylactic treatment. Galganezumab, a monoclonal antibody targeting the calcitonin gene-related peptide, reduced the weekly attacks of CH in one randomized, placebo-controlled trial for the prevention of episodic CH (eCH), but this effect was not detected in people with chronic CH (cCH). In this case series, we systematically monitored the efficacy and safety outcomes of adjunctive therapy in 11 people with refractory CH (failure of ≥ 3 prophylactic treatments; eCH n = 5, cCH, n = 6) who received galcanezumab (120-360 mg monthly) for 3 consecutive months. All participants received intermediate treatment with oral steroids or a great occipital nerve block ≥ 2 months before starting galcanezumab treatment. After galcanezumab treatment, the average number of weekly CH attacks and weekly days with any symptomatic treatment for CH decreased significantly from 16.0 ± 9.4 and 6.50 ± 3.59 before treatment to 1.8 ± 1.32 (p = 0.002) and 1.8 ± 3.36 (p = 0.001) at month 3 of treatment, respectively. Two participants with cCH showed no change in the number of attacks with galcanezumab. No serious adverse events were recorded. These data, along with those of previous real-world reports, suggest that galcanezumab may help people with refractory CH as an add-on treatment.","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"491-495"},"PeriodicalIF":1.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11721606/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142668644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A plain language summary describing changes in pain associated with uterine fibroids among women receiving relugolix combination therapy. 以通俗易懂的语言概述了接受瑞格列奈联合疗法的妇女在子宫肌瘤相关疼痛方面的变化。

IF 1.4

Pain management Pub Date : 2024-09-01 Epub Date: 2024-10-28 DOI: 10.1080/17581869.2024.2408114

Elizabeth A Stewart, Andrea S Lukes, Roberta Venturella, Juan-Camilo Arjona Ferreira, Yulan Li, Elke Hunsche, Rachel B Wagman, Ayman Al-Hendy

{"title":"A plain language summary describing changes in pain associated with uterine fibroids among women receiving relugolix combination therapy.","authors":"Elizabeth A Stewart, Andrea S Lukes, Roberta Venturella, Juan-Camilo Arjona Ferreira, Yulan Li, Elke Hunsche, Rachel B Wagman, Ayman Al-Hendy","doi":"10.1080/17581869.2024.2408114","DOIUrl":"10.1080/17581869.2024.2408114","url":null,"abstract":"What is this summary about?: This is a summary of two research studies (known as clinical trials) called LIBERTY 1 and LIBERTY 2. These studies compared how well a medicine called relugolix combination therapy and placebo worked in reducing heavy menstrual bleeding (periods) in women with uterine fibroids (published in a separate article referenced in the section: Where can readers find more information on these studies?). Researchers also looked at whether women with moderate to severe pain from uterine fibroids saw improvement in their worst pain symptoms after 24 weeks of treatment (results described in the present summary).What are the key takeaways?: Women with moderate to severe pain from uterine fibroids (menstrual or nonmenstrual pain) took either relugolix combination therapy or placebo (once daily by mouth) for 24 weeks. During the last 5 weeks of treatment, 65% of women taking relugolix combination therapy and 19% of women taking placebo reported having minimal or no menstrual pain. Similarly, 45% of women taking relugolix combination therapy and 22% of women taking placebo reported having minimal or no non-menstrual pain. During the same time period, 71% of the women taking relugolix combination therapy and 40% of women taking placebo reported their worst pain was reduced by about one third compared with the start of the study.What were the main conclusions reported by the researchers?: Women with moderate to severe pain from uterine fibroids taking relugolix combination therapy were more likely to have minimal or no pain from uterine fibroids after treatment compared with women taking placebo.Clinical Trial Registration: NCT03049735 (LIBERTY 1), NCT03103087 (LIBERTY 2) (ClinicalTrials.gov).","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"469-476"},"PeriodicalIF":1.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11728327/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142505799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sustained relief with spinal cord stimulator despite anterior lead migration: a case report. 脊髓刺激器在前导联线移位的情况下仍能持续缓解症状：病例报告。

IF 1.4

Pain management Pub Date : 2024-09-01 Epub Date: 2024-10-04 DOI: 10.1080/17581869.2024.2407283

Soun Sheen, Kent Nouri

引用次数: 0

Combatting opioid misuse, overuse and abuse: a systematic review of pharmacists' services and outcomes. 打击阿片类药物的误用、过量使用和滥用：药剂师服务和成果系统回顾。

IF 1.4

Pain management Pub Date : 2024-09-01 Epub Date: 2024-10-22 DOI: 10.1080/17581869.2024.2411930

Bhuvan Kc, Alian A Alrasheedy, Mohamed Izham Mohamed Ibrahim, Vibhu Paudyal, Christina Malini Christopher, Sunil Shrestha, Shakti Shrestha

{"title":"Combatting opioid misuse, overuse and abuse: a systematic review of pharmacists' services and outcomes.","authors":"Bhuvan Kc, Alian A Alrasheedy, Mohamed Izham Mohamed Ibrahim, Vibhu Paudyal, Christina Malini Christopher, Sunil Shrestha, Shakti Shrestha","doi":"10.1080/17581869.2024.2411930","DOIUrl":"10.1080/17581869.2024.2411930","url":null,"abstract":"Aim: To examine the range of services pharmacists provide and their impact on patient outcomes, harm reduction, and appropriate opioid use.Methods: Six databases were searched (MEDLINE, EMBASE, Scopus, PsycINFO, CENTRAL and Cochrane Methodology Register) from inception to March 2023. The protocol was registered in PROSPERO (CRD42023401895).Results: Twenty-nine studies identified five key areas of pharmacist interventions in opioid management-naloxone programs and opioid de-escalation, patient and primary healthcare providers' education and motivational interview, prescription monitoring and opioid risk screening, clinical pharmacy interventions (pharmacotherapy, medication review, prescribing, adherence monitoring), and collaborative healthcare approaches to promote optimal opioid use. Outcomes assessment indicated harm reduction, improved safety, increased non-opioid analgesic use, decreased opioid consumption, and enhanced pain management.Conclusion: This review underscores pharmacists' vital role in tackling opioid misuse, overuse and abuse, providing a foundation for evidence-based policies to minimize harm and promote optimal opioid use.","PeriodicalId":20000,"journal":{"name":"Pain management","volume":" ","pages":"519-529"},"PeriodicalIF":1.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11728331/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142505800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0